The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner
HB22.7 抗 CD22 单克隆抗体以序列依赖的方式增强硼替佐米介导的淋巴瘤杀伤活性。
期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/1756-8722-4-49
Martin, Shiloh M; Churchill, Eric; McKnight, Hayes; Mahaffey, Christopher M; Ma, Yunpeng; O'Donnell, Robert T; Tuscano, Joseph M
